Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140,241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Scarless wound healing programmed by core-shell microneedles.
Zhang Y, Wang S, Yang Y, Zhao S, You J, Wang J, Cai J, Wang H, Wang J, Zhang W, Yu J, Han C, Zhang Y, Gu Z. Zhang Y, et al. Among authors: wang h, wang j, wang s. Nat Commun. 2023 Jun 10;14(1):3431. doi: 10.1038/s41467-023-39129-6. Nat Commun. 2023. PMID: 37301874 Free PMC article.
Unmanned Aerial Vehicle Mediated Drug Delivery for First Aid.
Sheng T, Jin R, Yang C, Qiu K, Wang M, Shi J, Zhang J, Gao Y, Wu Q, Zhou X, Wang H, Zhang J, Fang Q, Pan N, Xue Y, Wang Y, Xiong R, Gao F, Zhang Y, Lu H, Yu J, Gu Z. Sheng T, et al. Among authors: wang h, wang y, wang m. Adv Mater. 2023 Mar;35(10):e2208648. doi: 10.1002/adma.202208648. Epub 2023 Jan 29. Adv Mater. 2023. PMID: 36563167
Ultrarapid-Acting Microneedles for Immediate Delivery of Biotherapeutics.
You J, Yang C, Han J, Wang H, Zhang W, Zhang Y, Lu Z, Wang S, Cai R, Li H, Yu J, Gao J, Zhang Y, Gu Z. You J, et al. Among authors: wang h, wang s. Adv Mater. 2023 Nov;35(45):e2304582. doi: 10.1002/adma.202304582. Epub 2023 Oct 11. Adv Mater. 2023. PMID: 37547966
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: wang h, wang z, wang j, wang m, wang c. Nat Cancer. 2023 Jun;4(6):860-871. doi: 10.1038/s43018-023-00578-z. Epub 2023 Jun 15. Nat Cancer. 2023. PMID: 37322367 Clinical Trial.
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: wang h, wang z, wang j, wang m, wang c. Nat Cancer. 2024 Jan;5(1):209. doi: 10.1038/s43018-023-00719-4. Nat Cancer. 2024. PMID: 38182915 No abstract available.
140,241 results
You have reached the last available page of results. Please see the User Guide for more information.